To study effectiveness of treatment with colistin based triple antimicrobial combination therapy versus minocycline based triple antimicrobial combination therapy in critically ill patients infected with carbapenem resistant Acinetobacter baumanni
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: B968- Other specified bacterial agents as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2024/06/069529
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients admitted in critical care unit of our hospital having either a bloodstream infection (BSI) and/or pneumonia due to MDR carbapenem resistant Acinetobacter Baumanni
Exclusion Criteria
Pregnant Patients,The presence of any of the following known clinical syndromes involving CRAB as a study pathogen which necessitate durations of antimicrobial therapies greater than 14 days: endocarditis, osteomyelitis, prosthetic joint infections, meningitis and/or other central nervous system infections.
Patients with known severe drug allergy to either of the study drugs or to ß-lactams.
Patients with polymicrobial infections.
Refusal to participate in study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of treatment failure after anti-CRAB treatment between minocycline versus colistin based triple antimicrobial therapy for carbapenem resistant Acinetobacter Baumannii Infection in critical care unit for a duration specified by protocolTimepoint: 3,5,7,10,12th day or within 24 hours after the end of study therapy
- Secondary Outcome Measures
Name Time Method Comparison of microbiological response, all-cause mortality after 28 days, change in SOFA score from baseline, duration of mechanical ventilation, duration of ICU stay, incidence of toxicities related to treatment medications between minocycline versus colistin based triple antimicrobial therapy for carbapenem resistant Acinetobacter Baumanni Infection in critical care unitTimepoint: 3,5,7,10,12th day or within 24 hours after the end of study therapy